Bayer, Nuvisan ink pact to create new research unit in Berlin
The strategic partnership will lay the foundation for a brand-new research entity to be established by Nuvisan in Berlin. At the same time, it will support Bayer's increased focus on the flexibility and productivity of its R&D operating model. Financial terms were not disclosed.
Berlin: Bayer AG recently announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an international service provider for clinical studies, laboratory services and contract manufacturing with several sites and clinics in Germany and France.
The strategic partnership will lay the foundation for a brand-new research entity to be established by Nuvisan in Berlin. At the same time, it will support Bayer's increased focus on the flexibility and productivity of its R&D operating model. Financial terms were not disclosed.
Read also: ProBioGen, Lava Therapeutics ink agreement for Novel Bispecific Molecule
Bayer and Nuvisan will cooperate closely in the coming years to build the new research centre. The transaction is expected to close mid of 2020 subject to the successful completion of the consultation process with the employee representatives and the preparations for taking over the research activities.
Read also: Zydus, China Medical System enter licensing agreement for desidustat
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd